Microba Life Sciences (ASX:MAP) Long-Term Debt: A$1.01 Mil (As of Dec. 2025)


What is Microba Life Sciences Long-Term Debt?

Microba Life Sciences ASX:MAP -2.63% Long-Term Debt is A$1.01 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Microba Life Sciences's Long-Term Debt for the quarter that ended in Dec. 2025 was A$1.01 Mil.

Microba Life Sciences's quarterly Long-Term Debt declined from Dec. 2024 (A$1.94 Mil) to Jun. 2025 (A$0.47 Mil) but then increased from Jun. 2025 (A$0.47 Mil) to Dec. 2025 (A$1.01 Mil).

Microba Life Sciences's annual Long-Term Debt stayed the same from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$0.00 Mil) but then increased from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.47 Mil).

Microba Life Sciences  (ASX:MAP) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Microba Life Sciences Long-Term Debt Related Terms

Microba Life Sciences Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Microba Life Sciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences Long-Term Debt Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Long-Term Debt
0.00 0.00 0.00 0.47

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only 0.51 0.00 1.94 0.47 1.01
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of A$1.01 Mil mean?
Microba Life Sciences (ASX:MAP) has a Long-Term Debt of A$1.01 Mil as of Dec. 2025.
Is Microba Life Sciences' Long-Term Debt too high?
Microba Life Sciences' current Long-Term Debt is A$1.01 Mil.
How does Microba Life Sciences' Long-Term Debt compare to TMO and DHR?
Microba Life Sciences' Long-Term Debt of A$1.01 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Microba Life Sciences's current Long-Term Debt is A$1.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 85.2% below its estimated fair value. The current Long-Term Debt is A$1.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Long-Term Debt is A$1.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microba Life Sciences Business Description

Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.